Six facts about amlodipine | Medycyna Faktow (J EBM)

PDF (Język Polski)

Published: Sep 30, 2020

DOI: https://doi.org/10.24292/01.MF.0320.8

Keywords:

amlodipine, arterial hypertension, pleiotropic effect, COVID-19

Filip M. Szymański

I Katedra i Klinika Kardiologii, Warszawski Uniwersytet Medyczny

Abstract

Amlodipine is one of the longest-used and best-tested antihypertensive drugs. It is widely used both as monotherapy, as well as a basis for drug combinations in single-pill combinations. Despite the long clinical experience with amlodipine, new research shows additional benefits of the drug in a variety of patients including patients with chronic diseases, elderly patients, with kidney disease, pregnant women or those exposed to COVID-19 infection. This paper summarizes the news on the use of amlodipine available at the beginning of 2020.

How to Cite

Szymański , F. M. (2020). Six facts about amlodipine. Medycyna Faktow (J EBM), 13(3(48), 331-335. https://doi.org/10.24292/01.MF.0320.8

Issue

Vol 13 No 3(48) (2020)

Section

Articles

Copyright © by Medical Education. All rights reserved.

References

1. Steffen HM. Use of calcium channel antagonists for the treatment of hypertension in the elderly. Drugs Aging. 2004; 21(9): 565-81.
2. Mason RP. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis. 2002; 165(2): 191-9.
3. Tabur S, Oğuz E, Sabuncu T et al. The effects of calcium channel blockers on nephropathy and pigment epithelium-derived factor in the treatment of hypertensive patients with type 2 diabetes mellitus. Clin Exp Hypertens. 2015; 37(3): 177-83.
4. Ostroumova OD, Kochetkov AI. [Effects of Amlodipine/Lisinopril Fixed-Dose Combination on Severity of Left Ventricular Hypertrophy and Parameters of Myocardial Stiffness in Patients With Hypertension]. Kardiologia. 2016; 56(11): 27-37.
5. Lee EY, Park JK, Lee W et al. Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud’s phenomenon: a double- blind, randomized, cross-over study. Rheumatology (Oxford). 2014; 53(4): 658-64.
6. Perna GP, Valle G, Cianfrone N et al. Amlodipine in ischaemic left ventricular dysfunction with mild to moderate heart failure. Clin Drug Investig. 1998; 16(4): 289-96.
7. opis odsyłaczaQasim S, Alamgeer, Kalsoom S et al. Appraisal of disease-modifying potential of amlodipine as an anti-arthritic agent: new indication for an old drug. Inflammopharmacology. 2020; Epub ahead of print. http://doi.org/10.1007/s10787-020-00692-9.
8. Karakus E, Halici Z, Albayrak A et al. Effects of Administration of Amlodipine and Lacidipine on Inflammation-Induced Bone Loss in the Ovariectomized Rat. Inflammation. 2016; 39(1): 336‐46. http://doi.org/10.1007/s10753-015-0254-6.
9. Derosa G, Cicero AF, Carbone A et al. Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. Eur J Pharm Sci. 2014; 51: 26‐33. http://doi.org/10.1016/j.ejps.2013.08.031.
10. Mancia G, Rea F, Ludergnani M et al. Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med. 2020; NEJMoa2006923.http://doi.org/10.1056/NEJMoa2006923.
11. Solaimanzadeh I. Nifedipine and Amlodipine Are Associated With Improved Mortality and Decreased Risk for Intubation and Mechanical Ventilation in Elderly Patients Hospitalized for COVID-19. Cureus. 2020; 12(5): e8069. http://doi.org/10.7759/cureus.8069.
12. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373(22): 2103-16. http://doi.org/10.1056/NEJMoa1511939.
13.Juraschek SP, Simpson LM, Davis BR et al. Effects of Antihypertensive Class on Falls, Syncope, and Orthostatic Hypotension in Older Adults: The ALLHAT Trial. Hypertension. 2019; 74(4): 1033‐40. http://doi.org/10.1161/HYPERTENSIONAHA.119.13445.
14. Feldman L, Vinker S, Efrati S et al. Amlodipine treatment of hypertension associates with a decreased dementia risk. Clin Exp Hypertens. 2016; 38(6): 545‐9. http://doi.org/10.3109/10641963.2016.1174249.
15. Greenan C, Murphy L, Yu LM et al. A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol. Trials. 2016; 17(1): 324. http://doi.org/10.1186/s13063-016-1449-3.
16. Yin WJ, Zhou LY, Li DY et al. Protective Effects of Amlodipine Pretreatment on Contrast-Induced Acute Kidney Injury And Overall Survival In Hypertensive Patients. Front Pharmacol. 2020; 11: 44. http://doi.org/10.3389/fphar.2020.00044.
17. Hwang YC, Yoon KH, Cha BS et al. Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension A randomized, open-label, active-controlled, superiority, parallel-group clinical trial. Int J Clin Pract. 2017; 71(9): e12987. http://doi.org/10.1111/ijcp.12987.
18. Ay SA, Cakar M, Karaman M et al. Amlodipine seems to be superior to valsartan in decreasing microalbuminuria in newly diagnosed hypertensive patients: a novel effect to be explained with hyperfiltration? Ren Fail. 2013; 35(3): 357‐60. http://doi.org/10.3109/0886022X.2012.755354.
19. Fici F, Ari Bakir E, Ilkay Yüce E et al. PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease. High Blood Press Cardiovasc Prev. 2020; 27(1): 43‐9. http://doi.org/10.1007/s40292-020-00358-1.
20. Prejbisz A, Dobrowolski P, Kosiński P et al. Management of hypertension in pregnancy: prevention, diagnosis, treatment and long‑term prognosis. Kardiol Pol. 2019; 77(7-8): 757‐806. http://doi.org/10.33963/KP.14904.
21. Malha L, August P. Safety of Antihypertensive Medications in Pregnancy: Living With Uncertainty. J Am Heart Assoc. 2019; 8(15): e013495. http://doi.org/10.1161/JAHA.119.013495.
22. Mito A, Murashima A, Wada Y et al. Safety of Amlodipine in Early Pregnancy. J Am Heart Assoc. 2019; 8(15): e012093. http://doi.org/10.1161/ JAHA.119.012093.
23. Jiang N, Liu Q, Liu L et al. The effect of calcium channel blockers on prevention of preeclampsia in pregnant women with chronic hypertension. Clin Exp Obstet Gynecol. 2015; 42(1): 79‐81.
24. Ghafarzadeh M, Shakarami A, Yari F et al. The comparison of side effects of methyldopa, amlodipine, and metoprolol in pregnant women with chronic hypertension. Hypertens Pregnancy. 2020: 1‐5. http://doi.org/10.1080/10641955.2020.1766489.
25. Torky HA, Shata A, Ahmad AM et al. Effect of amlodipine on blood flow of preovulatory follicle in women with clomiphene resistant polycystic ovaries: a randomized controlled trial. Arch Gynecol Obstet. 2020; 301(3): 845‐50. http://doi.org/10.1007/s00404-020-05471-z.
26. Vukadinović D, Scholz SS, Messerli FH et al. Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials. J Hypertens. 2019; 37(10): 2093‐103. http://doi.org/10.1097/HJH.0000000000002145.
27. Lee DW, Jung M, Wang HW et al. Systematic Review with Network Meta-Analysis: Comparative Efficacy and Safety of Combination Therapy with Angiotensin II Receptor Blockers and Amlodipine in Asian Hypertensive Patients. Int J Hypertens. 2019; 2019: 9516279. http://doi.org/10.1155/2019/9516279.
28. Kawada Y, Kubo T, Baba Y et al. Effects of Switching from Treatment with Amlodipine and Atorvastatin Using Two Pills to an Equal Dose of Single-Pill Therapy in Japanese Outpatients. Acta Med Okayama. 2020; 74(2): 103‐8. http://doi.org/10.18926/AMO/58267.

Most read articles by the same author(s)

Filip M. Szymański , Aldosterone antagonists in the treatment of poorly controlled and resistant arterial hypertension – results of the newest PATHWAY-2 trial , Cardiology in Practice: Vol 9 No 4 (2015)
Filip M. Szymański , Aleksander Prejbisz , Grzegorz Dzida , Place of fixed-dose combination containing perindopril and indapamide in the treatment of arterial hipertension – hypertension specialist, diabetologist and cardiologist’s point of view , Medycyna Faktow (J EBM): Vol 10 No 3(36) (2017)
Anna E. Płatek , Filip M. Szymański , Choice of hypotensive treatment in patients with risk factors and metabolic syndrome , Medycyna Faktow (J EBM): Vol 10 No 3(36) (2017)
Anna E. Płatek , Filip M. Szymański , Patient profiles in which the use of fixed-does perindopril/indapamide gives additional benefit , Medycyna Faktow (J EBM): Vol 9 No 3(32) (2016)
Krzysztof J. Filipiak , Aleksandra Gąsecka, Marcin Lewandowski , Anna E. Płatek , Filip M. Szymański , Beata Wożakowska-Kapłon, Andrzej Tykarski , Use of angiotensin-converting enzyme inhibitors and diuretics in antihypertensive therapy advised by Polish medical doctors – a final report from questionnaire ALMONDS study , Medycyna Faktow (J EBM): Vol 9 No 1(30) (2016)
Anna E. Płatek , Filip M. Szymański , Guidelines of the Polish Society of Arterial Hypertension as the newest document of diagnostics and treatment of hypertension. Place of the new hypotensive drugs on an example of zofenopril , Medycyna Faktow (J EBM): Vol 8 No 2(27) (2015)
Filip M. Szymański , Nebivolol – unique β-blocker with vasodilatory effect , Medycyna Faktow (J EBM): Vol 8 No 1(26) (2015)
Filip M. Szymański , Lercanidipine calcium channel blocker with unique properties – why should it be used in everyday clinical practice? , Medycyna Faktow (J EBM): Vol 7 No 4(25) (2014)
Filip M. Szymański , Ten reasons to choose dabigatran in everyday clinical practice , Medycyna Faktow (J EBM): Vol 7 No 3(24) (2014)
Filip M. Szymański , Lisinopril as an efficient and safe hypotensive agent – cardiologist’s point of view , Medycyna Faktow (J EBM): Vol 6 No 4(21) (2013)

1 2 > >>